Azitra, Inc.
AMEXAZTR heads into the post-earnings session with a fresh catalyst pulling in two directions at once — a Q1 EPS miss that landed today alongside a consumer skincare expansion that signals a strategic pivot for the Branford-based micro-cap biotech. Q1 results released this morning were the headline event. The company reported a loss per share of $0.25, nearly double the $0.12 consensus…
Snapshot as of 28 Jun 2026
AZTR heads into the post-earnings session with a fresh catalyst pulling in two directions at once — a Q1 EPS miss that landed today alongside a consumer skincare expansion that signals a strategic pivot for the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AZTR — free to start on ORTEX.
Sign up for free →Open AZTR on ORTEX